J.P. Morgan research suggests the probability of a U.S. recession in 2025 is dropping below 50% from its 60% peak, now that the Trump administration is pulling punches on some of its more aggressive tariff policies, allowing the S&P 500 to rebound after dipping into correction territory back in March. However, the risk is still high. But don’t worry — recessions and crashes do not necessarily spell doom for your portfolio. Instead of trying to time the market perfectly or panic-selling during downturns, whi ...

Investors might want to bet on HCA Healthcare (HCA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...

Summary of HCA Healthcare (HCA) 2025 Conference Call Company Overview - **Company**: HCA Healthcare (HCA) - **Industry**: Healthcare Services - **Event**: 2025 Conference Call on May 13, 2025 Key Points Financial Performance - **Q1 Performance**: Strong quarter with good volume growth and improved margins, attributed to operational leveraging and effective cost management [5][9] - **Net Revenue Growth**: Net revenue per unit increased by 3%, indicating solid top-line growth [9] - **EBITDA Growth**: EBITDA grew by 11% year-over-year, with a close to 9% growth when accounting for state supplemental payment impacts [33][34] Guidance and Sustainability - **Guidance Reaffirmation**: The company reaffirmed its guidance for the year, indicating a cautious approach due to the uncertain macro environment [6][8] - **Volume Growth Guidance**: Volume growth is projected at 3% to 4%, which is higher than the previous long-term target of 2% to 3% [26][32] Regulatory and Policy Environment - **Reconciliation Bill**: The draft bill is seen as largely maintaining current state supplemental payments, which is viewed positively, although it may limit future enhancement opportunities [11][12][13] - **Enhanced Premium Tax Credits (EPTCs)**: The company is advocating for the extension of EPTCs, which are crucial for coverage and cost of living for working families [15][16] Operational Insights - **Labor Trends**: The labor environment is stable, with improvements in retention rates returning to pre-pandemic levels. The company has invested in workforce development through partnerships with nursing schools [37][38][41] - **Professional Fees**: Professional fees are growing faster than inflation, with a reported 11% increase year-over-year. The company is working to stabilize these costs [42][43] Market Dynamics - **Ambulatory Surgery Centers (ASCs)**: The ASC business is experiencing mid-single-digit net revenue growth, although there have been slight volume declines in lower acuity cases [59][60] - **Non-Hospital Assets**: The company has expanded to 2,750 sites of care, with outpatient revenue growth outpacing inpatient revenue growth [61][62] Capital Allocation and Financial Strategy - **Leverage Ratio**: The leverage ratio stands at 3.1, within the targeted range of 2.75 to 3.75, indicating a strong balance sheet [65] - **Capital Investments**: The company plans to maintain a balanced approach to capital allocation, including investments in facilities, dividends, mergers and acquisitions, and share repurchases [65][68] Future Considerations - **Impact of Federal Health Policy Changes**: The company is preparing for potential adverse impacts from federal health policy changes and tariffs, with flexibility in capital allocation plans [67][68] Additional Insights - **Market Demand**: There are no current indications of deferred care or pull-forward utilization due to economic concerns, suggesting stable demand in the first quarter [28] - **Contracting with Payers**: The company is over 90% contracted for 2025 and 75% for 2026, indicating strong relationships with payers despite ongoing negotiations [50][51][55] This summary encapsulates the key insights and data points from the HCA Healthcare conference call, providing a comprehensive overview of the company's current performance, strategic outlook, and market dynamics.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdiction ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

HCA Healthcare (HCA) Q1 2025 Earnings Call April 25, 2025 04:54 PM ET Company Participants Frank Morgan - VP, Investor RelationsSam Hazen - CEOMike Marks - CFO & Executive Vice PresidentA.J. Rice - Managing DirectorWhit Mayo - Senior Managing DirectorBen Hendrix - Equity Research - Healthcare Services and Managed CareAndrew Mok - DirectorJoshua Raskin - Partner - Managed Care & ProvidersJohn Ransom - Managing Director, Director of Healthcare ResearchLance Wilkes - Managing DirectorBenjamin Rossi - Equity Re ...

HCA Healthcare, Inc. (HCA) reported first-quarter 2025 adjusted earnings per share (EPS) of $6.45, which outpaced the Zacks Consensus Estimate of $5.77. The bottom line advanced 20.3% year over year. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Revenues rose 5.7% year over year to $18.3 billion. The top line beat the consensus mark by 0.1%.The strong first-quarter results benefited from higher patient volumes, which led to an increased number of inpatient surgeries, emergency room v ...

HCA Healthcare, Inc. (NYSE:HCA) Q1 2025 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Frank Morgan - Vice President of Investor Relations Sam Hazen - Chief Executive Officer Mike Marks - Chief Financial Officer Conference Call Participants Ann Hynes - Mizuho Securities Pito Chickering - Deutsche Bank A.J. Rice - UBS Whit Mayo - Leerink Partners Ben Hendrix - RBC Capital Markets Sarah James - Cantor Fitzgerald Brian Tanquilut - Jefferies Andrew Mok - Barclays Capital Matthew Gillmo ...

HCA Healthcare (HCA) reported $18.32 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.7%. EPS of $6.45 for the same period compares to $5.36 a year ago.The reported revenue represents a surprise of +0.08% over the Zacks Consensus Estimate of $18.31 billion. With the consensus EPS estimate being $5.77, the EPS surprise was +11.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

HCA Healthcare (HCA) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.77 per share. This compares to earnings of $5.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.79%. A quarter ago, it was expected that this hospital operator would post earnings of $5.97 per share when it actually produced earnings of $6.22, delivering a surprise of 4.19%.Over the last four quarters, the c ...